26th Feb 2019 08:52
LONDON (Alliance News) - FTSE 100-listed drugmaker AstraZeneca PLC and its partner Merck & Co Inc said Tuesday its potentially blockbuster Lynparza cancer treatment had met the primary endpoint of one of its late stage clinical trials.
The Phase III POLO saw Lynparza - the brand name of olaparib - show "statistically-significant and clinically-meaningful improvement" in progression-free survival for patients with BRCA-mutated metastatic pancreatic cancer when compared to a placebo.
Full data from the trial is expected to be released at an unspecified medical meeting in the future.
AstraZeneca Executive Vice President for Oncology Research & Development Jose Baselga said: "This is the first positive Phase III trial of any PARP inhibitor in germline BRCA-mutated metastatic pancreatic cancer, a devastating disease with critical unmet need. The results of POLO provide further evidence of the clinical benefit of Lynparza across a variety of BRCA-mutated tumour types. We will discuss these results with global health authorities as soon as possible."
Shares in AstraZeneca were 0.7% lower at 6,247.00 pence on Tuesday.
Related Shares:
Astrazeneca